SCHEMBL7048894

SCHEMBL7048894

CC(=O)c1ccc2c(c1)[C@H](N)[C@H](O)C(C)(C)O2

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 2/20 0.43
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9194748 1.00 ABCC9 (0.43) ABCC9KDM4E
SCHEMBL9194740 1.00 ABCC9 (0.43) ABCC9KDM4E
SCHEMBL7049232 1.00 ABCC9 (0.43) ABCC9KDM4E
Hydrochloric Acid SCHEMBL16863561 0.99 ABCC9 (0.42) ABCC9KDM4E
Sulfuric Acid SCHEMBL16027584 0.93 ABCC9 (0.41) ABCC9KDM4E
SCHEMBL27535324 0.87 ABCC9 (0.36) ABCC9KDM4E
SCHEMBL9200557 0.81 CA12 (0.43) ABCC9KDM4E
SCHEMBL9200569 0.81 CA12 (0.43) ABCC9KDM4E
SCHEMBL9200576 0.81 CA12 (0.43) ABCC9KDM4E
SCHEMBL15257366 0.80 KDM4E (0.41) ABCC9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318892-A1 PRODRUG COMPOUNDS PROXIMAGEN LIMITED (GB) 2016-11-03 US disclosed
US-20160318892-A1 PRODRUG COMPOUNDS PROXIMAGEN LIMITED (GB) 2016-11-03 US disclosed
WO-2015097461-A1 PRODRUG COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-07-02 WO disclosed
EP-1091950-B1 SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2003-04-09 EP disclosed
US-6395909-B1 DRUGS FOR ANTICONVULSANTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-28 US disclosed
US-20010027248-A1 Novel receptor SMITHKLINE BEECHAM P.L.C. 2001-10-04 US disclosed
US-6245893-B1 ANTICONVULSANTS, USE IN TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2001-06-12 US disclosed
EP-1091950-A1 SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000000484-A1 SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-01-06 WO disclosed
US-5985334-A Screening methods to identify anti-convulsant compounds SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-16 US disclosed
EP-0807122-A1 NOVEL RECEPTOR SMITHKLINE BEECHAM PLC (GB) 1997-11-19 EP disclosed
WO-1996018650-A1 NOVEL RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 1996-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027248-A1 Novel receptor ADGRF1, TACR2, GPR4 ABCC9 2047/4885KDM4E 4395/4885
US-20160318892-A1 PRODRUG COMPOUNDS SCN1B, CACNA1E, SCN2B ABCC9 370/4885KDM4E 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.